Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR202 (Felzartamab) in Relapsed/Refractory Multiple Myeloma
NCT01421186Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Jul 2011
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of felzartamab in multiple myeloma (MM) (2 arms), sponsored by MorphoSys AG. Primary endpoints: Maximum Tolerated Dose and Anti-Drug Antibodies up to 3 years. Started Jul 2011; status: completed.
02
Drugs
felzartamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01421186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421186.